GYRE vs SION
GYRE: A China-based biopharmaceutical company generating revenue from approved antifibrotic treatments while advancing late-stage candidates for liver and other organ fibrosis in the U.S. market. SION: A clinical-stage biotech pioneering the first drugs to directly stabilize CFTR's NBD1 domain, tackling the "undruggable" target in cystic fibrosis.
Side-by-side fundamentals
| Metric | GYRE | SION | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.94 | $45.03 | |
| Market cap as of 2026-07-23 | $667M | $2.1B | |
| P/E as of 2026-07-23 | 132.62 | n/a | |
| PEG as of 2026-07-23 | n/a | -0.90 | |
| Net margin as of 2026-07-23 | -5.4% | n/a | |
| Gross margin as of 2026-07-23 | +95.1% | n/a | |
| Operating margin as of 2026-07-23 | -0.1% | n/a | |
| ROE as of 2026-07-23 | -6.3% | -27.3% | GYRE higher |
| ROA as of 2026-07-23 | -4.0% | -25.9% | GYRE higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +16.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +4.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 2.36 | 1.40 | |
| 1-year return as of 2026-07-22 close | -17.8% | +170.7% | SION higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.